Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal cancer.
While DNA damaging agents such as platinum and PARP inhibitors have derived clinical benefits, acquired resistance invariably develops.
Hence there is an urgent need for novel therapeutic strategies to overcome acquired resistance.
